Sakar Healthcare growth ratios

·UnclassifiedChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+41.8%+15.8%+15.0%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+38.7%+29.5%+15.8%
+57.4%+41.8%+11.9%
+74.2%+50.0%−8.5%
+71.9%+41.3%−14.4%
+15.8%+6.8%+15.6%
+13.7%+8.8%+51.3%
+38.3%+45.5%−26.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SAKAR₹946.50

Sakar Healthcare Limited

· Unclassified
₹ CrorePeersMACPOWERSERVOTECHKAPSTONTHEJOBETAMcap ₹2,106 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+15.0+15.8+41.8—
EBITDA Growth—+15.8+29.5+38.7—
EBIT Growth—+11.9+41.8+57.4—
Net Income Growth—-8.5+50.0+74.2—
EPS Growth—-14.4+41.3+71.9—
Total Assets Growth—+15.6+6.8+15.8—
Total Equity Growth—+51.3+8.8+13.7—
Cash from Operations Growth—-26.6+45.5+38.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.